JIUYUAN GENE (02566) experienced a significant surge in its stock price during Wednesday's intraday trading, with shares soaring 5.63%. This upward movement comes on the heels of the company's recently released interim financial results, which paint a mixed picture of its performance in the first half of 2025.

According to the interim report, JIUYUAN GENE recorded a revenue of RMB 639 million for the six months ended June 30, 2025, representing a 9.05% year-on-year decline. The company's net profit attributable to shareholders also saw a decrease, falling 14.4% to RMB 90.174 million. Despite these overall declines, investors appear to be focusing on positive aspects of the report, particularly the company's performance in its orthopedic segment.

A key highlight from the results was the over 10% year-on-year increase in orthopedic product sales volume, with hospital penetration rates continuing to improve. This growth in a crucial product line seems to have bolstered investor confidence. Furthermore, management's commitment to implementing differentiated commercial policies aimed at stabilizing existing markets and cultivating new ones has likely contributed to the positive market sentiment. As the company focuses on achieving steady growth in full-year business revenue, investors seem optimistic about JIUYUAN GENE's future prospects, driving the stock's impressive intraday performance.